Effect of letrozole on plasma lipids, triglycerides, and Estradiol in postmenopausal women with metastatic breast cancer

Oncologist

Volumn 15, Issue 11, 2010, Pages 1159-1163

  Zidan, Jamal ^a,d   Chetver, Lika ^a   Hussein, Osamah ^b   Zucker, Miriam ^c  

^a Oncology Institute   (Israel)

^b Internal Medicine Department   (Israel)

^c Rebecca Sieff Government Hospital   (Israel)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Breast cancer; Estradiol; Letrozole; Lipids; Safety; Triglyceride

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ESTRADIOL; FLUOROURACIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LETROZOLE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NAVELBINE; PACLITAXEL; TRASTUZUMAB; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BREAST CANCER; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; LIPIDS; MIDDLE AGED; NEOPLASM METASTASIS; NITRILES; POSTMENOPAUSE; PROSPECTIVE STUDIES; TRIAZOLES; TRIGLYCERIDES;

EID: 78649919613     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0222     Document Type: Article

References (19)

1. Wakeling AE, Valcaccia B, Newboult E et al. Non-steroidal antioestrogens- receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. J Steroid Biochem 1984;20:111-120.
2. Powles TJ, Hickish T, Kanis JA et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometryin healthy premeno-pausal and postmenopausal women. J Clin Oncol 1996;14:78-84.
3. Zidan J, Keidar Z, Basher W et al. Effects of tamoxifen on bone mineral density and metabolism in postmenopausal women with early-stage breast cancer. Med Oncol 2004;21:117-121.
4. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003;348:2431-2442.
5. Longcope C, Baker R, Johnston CC Jr. Androgen and estrogen metabolism: Relationship to obesity. Metabolism 1986;35:235-237.
6. Berrino F, Muti P, Micheli A et al. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 1996;88:291-296.
7. Boeddinghaus IM, Dowsett M. Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors. J Steroid Biochem Mol Biol 2001;79:85-91.
8. Elisaf MS, Bairaktari ET, Nicolaides C et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 2001; 37:1510-1513.
9. Geisler J, Haynes B, Anker G et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in randomized, cross-over study. J Clin Oncol 2002;20:751-757.
10. Banerjee S, Smith IE, Folkerd L et al. Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived re-sorption during neoadjuvant therapy in the impact trial. Ann Oncol 2005; 16:1632-1638.
11. Sawada S, Sato K, Kusuhara M et al. Effect ofanastrozole and tamoxifen on lipid metabolism inJapanese postmenopausal women with early breast cancer. Acta Oncol 2005;44:134-141.
12. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 2005;23:619-629.
13. Harper-Wynne C, Ross G, Sacks N et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indi- ces in postmenopausal women: A pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev 2002;11:614-621.
14. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in post-menopausal women after 5 years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-1802.
15. Gershanovich M, Chaudri HA, Campos D et al. Letrozole, a new oral aro-matase inhibitor: Randomized trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann Oncol 1998;9: 639-645.
16. Breast International Group (BIG) 1-98 Collaborative Group; Thrlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353: 2747-2757.
17. Wojtacki J, Kruszewski W, Sliwinska M et al. Effect of non-steroidal aro-matase inhibitors (AI) on serum lipid profile in patients with breast cancer. Preliminary report [abstract 146]. Eur J Cancer 2000;36:S5.
18. Dixon JM, Renshaw L, Young O et al. Letrozole suppresses plasma estra-diol and estrone sulphate more completely than anastrozole in postmeno-pausal women with breast cancer. J Clin Oncol 2008;26:1671-1676.
19. Bajetta E, Martinetti A, Zilembo N et al. Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: Effect on estrogens and bone metabolism. Ann Oncol 2002;13:1059-1066.